You are here

Immunext, Inc.

Company Information
Address
1 Medical Center Dr
Lebanon, NH 03756-1000
United States


https://www.immunext.com

Information

UEI: SBSALV1MKHA3

# of Employees: 15


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR-Success: Small Company Makes Big Strides in Treating Autoimmune Diseases and Cancers

    The U.S. spends billions of dollars in drug development every year hoping to cure disease, end suffering, and extend life. The problem is that of the thousands of pharmaceuticals that enter the drug pipeline, only a small percentage make it out. “Pharma has big challenges in trying to...

Award Charts




Award Listing

  1. Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases

    Amount: $990,946.00

    Glucocorticoids (GC) are a class of drugs with overwhelming anti-inflammatory activities. However, dose limiting toxicities (DLT) caused by systemic GC exposure prevent GC from being a true panacea in ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  2. Targeting leukocyte metabolism to treat human autoimmune disease

    Amount: $299,502.00

    ImmuNext has defined an anti MCTmonoclonal antibodymAbthat will be developed for the treatment of human autoimmune diseaseThe membrane monocarboxylate nutrient transporter SLCAMCTis a multi pass trans ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Targeting leukocyte metabolism to treat human autoimmune disease

    Amount: $2,987,732.00

    ImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient transporter SLC16A1 (MCT1) is a ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  4. Targeting the checkpoint regulator VISTA for treatment of inflammatory disease

    Amount: $299,938.00

    ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibody mAb that we aim to bring to the clinic for the treatment of human autoimmune disease VISTA is a member of the hi ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  5. Targeting the checkpoint regulator VISTA for treatment of inflammatory disease

    Amount: $2,988,407.00

    ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibodymAbthat we aim to bring to the clinic for the treatment of human autoimmune diseaseVISTA is a member of the highly s ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  6. Safe and effective anti CD antibodies for therapeutic intervention

    Amount: $1,824,382.00

    Abstract CD CD L is a key target for immunomodulation due to its central role in controlling the activation of the immune system This well studied immune switch has been the focus of extensi ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  7. Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

    Amount: $1,949,257.00

    DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a devastating autoimmune disease that most commonly affects women in their child bearing years SLE attacks multiple organ sy ...

    STTRPhase II2014Department of Health and Human Services National Institutes of Health
  8. Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention

    Amount: $290,914.00

    DESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 t ...

    STTRPhase I2013Department of Health and Human Services National Institutes of Health
  9. Safe and effective anti CD154 antibodies for therapeutic intervention

    Amount: $2,960,698.00

    DESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for ...

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health
  10. Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The immune system depends upon an exquisite balance between positive and negative signals to maintain proper function. However, disruptions of this balance can lea ...

    STTRPhase I2012Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government